Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
We wanted to examine the immunogenicity and safety of a shortened specific immunotherapy in contrast to the standard specific immunotherapy. Therefore, we challenged 12 patients for 14 weeks with the standard specific scheme and 22 patients for 6 weeks with the shortened scheme.
Epistemonikos ID: 1527516092fa62295cb8f4a96aa0cd9b0b963c53
First added on: May 04, 2024